Publications by authors named "Olaf Prien"

Claim this Profile
M
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Päivi Taavitsainen, Olaf Prien, Marja Kähkönen, Michael Niehues, Timo Korjamo

Drug Metab Dispos· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.
Olaf Panknin, Andrea Wagenfeld, Wilhelm Bone, Eckhard Bender, Katrin Nowak-Reppel, Olaf Prien

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats.
Päivi Taavitsainen, Hille Gieschen, Timo Korjamo, Marja Kähkönen, Chira Malmström, Olaf Prien

Xenobiotica· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Christian Zurth, Mikko Koskinen, Robert Fricke, Olaf Prien, Timo Korjamo

Eur J Drug Metab Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Neal Shore, Christian Zurth, Robert Fricke, Hille Gieschen, Kristina Graudenz, Olaf Prien

Target Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Marcus-Hillert Schultze-Mosgau, Joachim Höchel, Olaf Prien, Torsten Zimmermann, Ashley Brooks

Clin Pharmacokinet· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,3'-dipyridyl BINOL ligands. Synthesis and application in enantioselective addition of Et2Zn to aldehydes.
Robert R Milburn, S M Shakil Hussain, Olaf Prien, Zaheer Ahmed, Victor Snieckus

Org Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The gatekeeper: friend or foe in identifying the next generation of kinase inhibitors.
Olaf Prien

ChemMedChem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors.
Rolf Jautelat, Thomas Brumby, Martina Schäfer, Hans Briem, Gerhard Eisenbrand, Olaf Prien

Chembiochem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability.
Olaf Prien

Chembiochem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis